News

UnitedHealth Group executives attribute the increase in revenue and earnings to growth at both its Optum and UnitedHealthcare divisions.

Researchers developed a new multi-cancer blood screening test to detect early-stage cancers and found it had a high level of accuracy.

Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.

New sign-up rates for plan selections total 18%.

After anticipation of integrating two health systems for the last two years, Essentia Health and Marshfield Clinic Health System (MCHS) recently announced their merger will no longer be in effect.

The transaction is valued at about $575 million. The sale is part of Rite Aid’s restructuring plan after filing for bankruptcy in October 2023.

The Philadelphia-based insurer has selected four winners.

Research findings reported in Health Affairs today show that relatively small increases in out-of-pocket costs for HIV preexposure prophylaxis (PrEP) have a disproportionate effect on the proportion of people who don't get the prescription filled.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

The American Gastroenterological Association recommendations do not take a stand for or against using probiotics for those with intermittent pouchitis.

COVID-19 vaccines are currently administered intramuscularly. Studies indicate that intramuscular vaccine administration may not effectively generate antibodies and T cells against SARS-CoV-2 in the respiratory tract mucosa.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

Lipoprotein(a) is a cardiovascular disease risk factor that does not change with diet and exercise. There are no FDA-approved treatments, but two candidates are in phase 3 trials.

We caught up recently with William Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board. Shrank has held several executive positions with health insurers, most recently Humana. He is now a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California.

The 10 drugs selected by CMS for price negotiation are priced about three times higher in the United States than in other countries, finds a new study by the Commonwealth Fund.

Results point to the benefit of adding Darzalex (daratumumab) to Velcade-Revlimid-dexamethasone triplet therpay, although serious side effects seem be slightly more common when Darzalex is added.

Trial results revealed that tumors shrank in 40% of patients who received the 10-mg dose of tarlatamab and in about 32% of those who received the 100-mg dose.

Results reported in JAMA Psychiatry today show no difference in effectivenes between at-home cranial stimulation and sham treatment.

A subset of natural killer cells may be a potential target for the development of agents protective against MS.

Inflammatory bowel disease (IBD) clinical trials often involve participants getting numerous endoscopies. Cutting back on the number of endoscopies and using noninvasive tests instead was one of the ideas discussed for how to improve clinical trial design.

We asked 16 industry professionals what their predictions are for health care in 2024.

Brent Dover is the CEO of Carta Healthcare. He predicts that AI use will reach new heights.

Matt Hollingsworth is the Chief Innovation Officer and Co-Founder of Carta Healthcare. He said there will be a growing need for technology in 2024.

Greg Baker is the CEO of AffirmedRx. He predicts that "transparent PBMs will gain traction" in 2024.

François de Brantes, M.S., MBA is a senior partner at HVC Incentives Advisory Group LLC and a member of Managed Healthcare Executive editorial advisory board. He predicts "price distortions will be revealed" in 2024.

Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.

Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.